“on the adult side, here, again, we've seen a very strong growth in 2024 that we continue to expect significant growth just because we are expanding access in more mature markets with our Prevnar 20 adults.”

In context

“longside our great collaboration with The Gavi organization, we have a commercial organizations where we have demonstrated this year a double-digit growth of our Prevnar franchise. So a great execution in emerging markets. Now in the developed markets, following the EMA and the Japan approval, remember in March only of 2024, we've started to gain VTC approval and funding. And where we start to see that, we see that we are recapturing very quickly some of the business that went to competition. So give you an example, in Japan. Prevnar 20, as I said was approved in March. We got the VTC recommendation in October, and our market share in first dose went from 3% in September to 86% in December. So we see that Prevnar 20 gets approved, we really have an opportunity to regain that business. And on the adult side, here, again, we've seen a very strong growth in 2024 that we continue to expect significant growth just because we are expanding access in more mature markets with our Prevnar 20 adults. Albert Bourla: And Aamir, in the U.S.? Aamir Malik: In the U.S., let me start with the adult market. We have, right now, a very strong position in the adult market. Now we are going to face competitive pressure over the course of 2025 from capacity. But we are confident that we will continue to maintain meaningful market share. A lot of that has to do with our commercial execution, as well as the fact that many accounts, particularly nonretail accounts, prefer to stock a single vaccine. So we'll see that evolve over the course of the year. And while we don't think that there's much catch-up opportunity in the 65-plus, we also think there is growth opportunity in the 50 to 64 age group that brings about 30 million adults into the eligible population. So those will be the dynamics in adult.”